Amylyx Pharmaceuticals, Inc.
AMLX
$32.92
-$0.96-2.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -91.05% | 30.16% | |||
| Gross Profit | 91.05% | -30.16% | |||
| SG&A Expenses | 35.60% | 5.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.37% | 19.60% | |||
| Operating Income | -4.37% | -19.60% | |||
| Income Before Tax | -5.18% | -25.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.18% | -25.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.18% | -25.11% | |||
| EBIT | -4.37% | -19.60% | |||
| EBITDA | -4.51% | -19.68% | |||
| EPS Basic | -4.58% | -24.30% | |||
| Normalized Basic EPS | -4.58% | -6.62% | |||
| EPS Diluted | -4.58% | -24.30% | |||
| Normalized Diluted EPS | -4.58% | -6.62% | |||
| Average Basic Shares Outstanding | 0.57% | 0.66% | |||
| Average Diluted Shares Outstanding | 0.57% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||